Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Retained Earnings (2016 - 2025)

Plus Therapeutics has reported Retained Earnings over the past 16 years, most recently at -$515.9 million for Q4 2025.

  • Quarterly Retained Earnings fell 4.54% to -$515.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$515.9 million through Dec 2025, down 4.54% year-over-year, with the annual reading at -$515.9 million for FY2025, 4.54% down from the prior year.
  • Retained Earnings was -$515.9 million for Q4 2025 at Plus Therapeutics, down from -$510.2 million in the prior quarter.
  • Over five years, Retained Earnings peaked at -$436.2 million in Q1 2021 and troughed at -$515.9 million in Q4 2025.
  • The 5-year median for Retained Earnings is -$475.1 million (2023), against an average of -$475.0 million.
  • Year-over-year, Retained Earnings decreased 2.32% in 2021 and then fell 5.61% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$446.9 million in 2021, then decreased by 4.54% to -$467.2 million in 2022, then decreased by 2.85% to -$480.5 million in 2023, then decreased by 2.7% to -$493.5 million in 2024, then fell by 4.54% to -$515.9 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Retained Earnings are -$515.9 million (Q4 2025), -$510.2 million (Q3 2025), and -$505.7 million (Q2 2025).